Gatifloxacin: A review of its use in the management of bacterial infections

Drugs

Volumn 62, Issue 1, 2002, Pages 169-207

  Perry, Caroline M ^a   Ormrod, Douglas ^a   Hurst, Miriam ^a   Onrust, Susan V ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Gatifloxacin; Infection; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

ALUMINUM; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CLARITHROMYCIN; DIGOXIN; ERYTHROMYCIN; GATIFLOXACIN; IRON; LEVOFLOXACIN; MAGNESIUM; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THEOPHYLLINE;

ABDOMINAL PAIN; ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; CLINICAL TRIAL; DIARRHEA; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; INTESTINE FLORA; MULTICENTER STUDY; NAUSEA; PHARMACODYNAMICS; PNEUMONIA; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; TASTE DISORDER; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION; VAGINITIS; VERTIGO; VOMITING;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0036179918     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262010-00007     Document Type: Review

References (174)

1. Gatifloxacin
2. The new fluoroquinolones: A critical review
3. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases
4. Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: Contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997)
5. Gatifloxacin (AM-1155, CG 5501) susceptibility testing interpretive criteria and quality control guidelines for dilution and disk (5-microgram) diffusion methods
6. Activity of BMS284756 against 2.681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States
7. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States
8. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme
9. Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program, 1997 and 1998
10. CG5501 - In vitro study against clinical isolates including Chlamydia ssp. and Mycobacterium tuberculosis
11. Comparative in vitro activity of gatifloxacin with other antimicrobial agents against clinical bacterial isolates from Argentina
12. Comparative in vitro activity of gatifloxacin
13. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms
14. In vitro antibacterial activities of gatifloxacin (AM-1155) against clinical pathogens recently isolated from various infections
15. The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada-1997 results from the SENTRY Antimicrobial Surveillance Program
16. Survey of blood stream infections attributable to gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program
17. Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997-1999
18. Antimicrobial activity of gatifloxacin compared to seven other compounds tested against Gram-positive organisms isolated at 10 cancer-treatment centers
19. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci
20. In vitro activity of gatifloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis
21. Activity of quinolones against Chlamydia pneumoniae
22. In vitro activities of several fluoroquinolones against Mycobacterium tuberculosis
23. In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
24. In vitro activity of gatifloxacin against Gram-negative isolates from cancer patients
25. Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997
26. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998)
27. Antibacterial activity of gatifloxacin against Enterobacteriaceae and nonfermenting Gram-negative bacteria
28. Comparative activity of 7 quinolones against non-glucose fermenting Gram-negative bacilli isolated from cancer patients
29. Comparative antimicrobial activity of gatifloxacin tested against Campylobacter jejuni including fluoroquinolone-resistant clinical isolates
30. In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species
31. In-vitro activities of gatifloxacin, sparfloxacin and trovafloxacin against 103 strains of Legionella spp
32. Gatifloxacin: A new fluoroquinolone for use in community-acquired pneumonia and other infections
33. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155) trovofloxacin, clinafloxacin, levofloxacin and ciprofloxacin
34. Quinolone activity against anaerobes
35. In vitro activities of gatifloxacin, two other quinolones, and five nonquinolone antimicrobials against obligately anaerobic bacteria
36. In vitro activity of gatifloxacin tested against anaerobic bacteria by reference agar dilution and Etest methods
37. Antianaerobic activity of gatifloxacin
38. In vitro activity of gatifloxacin against anaerobic bacteria isolated from pulmonary specimens
39. Activity of gatifloxacin compared to those of five other quinolones versus aerobic and anaerobic isolates from skin and soft tissue samples of human and animal bite wound infections
40. Gatifloxacin: Efficacy against ciprofloxacin-resistant S. pneumoniae and beta-lactamase-positive H. influenzae in an experimental acute otitis media infection model in gerbils
41. In vivo antibacterial activity of gatifloxacin
42. Administration of gatifloxacin in an in vitro model of the treatment of bacterial cystitis
43. Efficacy of gatifloxacin in experimental Escherichia coli meningitis
44. Mechanisms of fluoroquinolone resistance: An update 1994-1998
45. Mechanisms of fluoroquinolone resistance
46. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season
47. Mechanisms of fluoroquinolone resistance and the role of topoisomerase activity
48. Contributions of the 8-methoxy group of gatifloxacin to resistance, selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae
49. Mechanisms and frequency of resistance to gatifloxacin in comparison with ciprofloxacin in Staphylococcus aureus
50. Susceptibilities of Neisseria gonorrhoeae isolates containing amino acid substitutions in GyrA, with or without substitutions in ParC, to newer fluoroquinolones and other antibiotics
51. Association of alterations in parC and GyrA proteins with resistance of clinical isolates of Enterococcus faecium to nine different fluoroquinolones
52. Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae
53. Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America
54. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract
55. Synergistic activity of gatifloxacin in combination with other antimicrobial agents against Pseudomonas and related species
56. Activity of gatifloxacin in combination with other antibiotics
57. In vitro and in vivo postantibiotic effects of gatifloxacin, a new quinolone
58. Postantibiotic effects of gatifloxacin against Gram-positive and -negative organisms
59. Inhibition of the HERG potassium channel by fluoroquinolone antibacterials: Correlation with risk for clinically significant QT interval prolongation
60. Single- and multiple-dose pharmacokinetics of AM-115, a new 6-fluoro-8-methoxy quinolone in humans
61. Phase I study of gatifloxacin, a new quinolone. I. Single-dose study
62. Phase I study of gatifloxacin, a new quinolone. II. Multiple-dose study
63. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose
64. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium
65. Safety and pharmacokinetics of a single oral dose of gatifloxacin in patients with moderate to severe hepatic impairment
66. Interchangeability of 400-mg intravenous and oral gatifloxacin in healthy adults
67. Age and gender effects on the pharmacokinetics of gatifloxacin
68. Single dose pharmacokinetics of the R- and S-enantiomers of gatifloxacin in volunteers
69. A dose-escalation study of the safety, tolerability, and pharmacokinetics of intravenous gatifloxacin in healthy adult men
70. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers
71. Effects of ferrous sulfate, green tea, and milk on the pharmacokinetics of gatifloxacin in healthy humans
72. Effect of a high-fat meal on the bioavailability of gatifloxacin in healthy volunteers
73. Safety, tolerance and food effect after single and multiple oral doses of gatifloxacin, a new fluoroquinolone antibiotic, to healthy Caucasian volunteers
74. Expanded activity and utility of the new fluoroquinolones: A review
75. Tissue penetration of gatifloxacin into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AMS) after administration of a single 400 mg oral dose
76. Pharmacokinetie and clinical studies of gatifloxacin on otorhinolaryngological infections
77. Pharmacokinetic and clinical studies of gatifloxacin on otorhinolaryngological infections
78. Basic and clinical studies on gatifloxacin in obstetrics and gynecology
79. Gatifloxacin: Plasma and urine concentrations and penetration into prostatic and seminal fluid after single oral dose of 400 mg in volunteers
80. Clinical study of gatifloxacin in prostatitis
81. Genital tissue penetration and clinical evaluation of gatifloxacin, a new fluoroquinolone, in obstetrics and gynecology
82. Penetration of AM- 1155 into female genital tissue
83. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract
84. Clinical evaluation of gatifloxacin, a new fluoroquinolone, in chronic respiratory tract infections: Its penetration into sputum and bactericidal effect
85. Early phase II clinical study of gatifloxacin, an oral new quinolone, for infections in the field of internal medicine
86. Late-phase-II clinical study of gatifloxacin, an oral new quinolone, in respiratory tract infections
87. Pharmacokinetic study of gatifloxacin: Penetration of gatifloxacin into cerebrospinal fluid
88. Evidence of different profiles of side effects and drug-drug interactions among the quinolones: The pharmacokinetic standpoint
89. Pharmacokinetics of gatifloxacin, a new quinolone, in elderly patients
90. Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise
91. The effect of varying degrees of renal impairment on the pharmacokinetics and safety of gatifloxacin
92. Pharmacokinetics of gatifloxacin in patients with impaired renal function
93. Effects of aluminum hydroxide and cimetidine on the pharmacokinetics of gatifloxacin in healthy humans
94. Open-label, non-randomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers
95. Influence of oxycodone on the bioavailability of gatifloxacin
96. Lack of effect of multiple-dose gatifloxacin on oral glucose tolerance, glucose and insulin homeostasis, and glyburide pharmacokinetics in patients with type II non-insulin-dependent diabetes mellitus
97. Pharmacokinetics and pharmacodynamics of fluoroquinolones
98. Ofloxacin: A reappraisal of its use in the management of genitourinary tract infections
99. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract
100. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections
101. Pharmacokinetics and safety of gatifloxacin in combination with ferrous sulfate or calcium carbonate in healthy volunteers
102. Lack of interaction between concomitantly administered gatifloxacin and digoxin
103. Influence of gatifloxacin, a new quinolone antibacterial, on pharmacokinetics of theophylline
104. Effects of gatifloxacin (GTX), on the pharmacokinetics of theophylline in healthy young volunteers
105. Dose-finding study of gatifloxacin, a new oral, quinolone, in chronic respiratory tract infection
106. Comparative study on 3-day and 7-day treatment with gatifloxacin in acute uncomplicated cystitis
107. Study on the clinical value of gatifloxacin in complicated urinary tract infections associated with indwelling catheters
108. Dose-finding study of gatifloxacin in complicated urinary tract infections
109. Clinical late phase II study of gatifloxacin in genitourinary tract infections
110. Clinical early phase II study of gatifloxacin in urinary tract infections
111. Clinical study of gatifloxacin in the treatment of male urethritis
112. Clinical evaluations of gatifloxacin in dermatology
113. Fundamental and clinical studies of gatifloxacin in ophthalmology
114. Clinical evaluation for gatifloxacin in bacterial ocular infections
115. Basic and clinical studies of gatifloxacin in dental and oral surgery
116. Basic and clinical studies of gatifloxacin in oral surgery
117. Clinical evaluation of a fluoroquinolone antimicrobial drug (gatifloxacin) in the field of surgical infections
118. Basic and clinical studies of gatifloxacin in the field of surgery
119. Treating community-acquired pneumonia in hospitalized patients: Gatifloxicin vs ceftriaxone/clarithromycin
120. Treating community-acquired pneumonia with once-daily gatifloxacin vs twice-daily clarithromycin
121. The efficacy and safety of once-daily oral gatifloxacin (400mg) versus twice-daily oral clarithromycin (500mg) in patients with community-acquired pneumonia
122. Once-daily gatifloxacin versus twice-daily Augmentin® 500 mg amoxicillin/125 mg clavulanic acid in the treatment of patients with bacterial community-acquired pneumonia (CAP)
123. A double-blind comparative study of gatifloxacin and levofloxacin in pneumonia
124. Treating community-acquired pneumonia with once-daily gatifloxacin vs once-daily levofloxacin
125. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis
126. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis
127. A comparison of two oral dose regimens of gatifloxacin (200mg once daily or 400mg once daily) to Augmentin® (500mg amoxicillin/125mg clavulanic Acid t.i.d.) in the treatment of patients with an acute exacerbations of chronic bronchitis
128. Once-daily oral gatifloxacin (400mg) versus thrice-daily oral Augmentin® (500 mg amoxicillin/125 mg clavulanic acid) in the treatment of patients with acute sinusitis
129. Gatifloxacin vs clarithromycin in the management of acute sinusitis
130. A randomized, double-blind, multicenter study of gatifloxacin vs. trovafloxacin in acute maxillary sinusitis
131. A double-blind comparative study of gatifloxacin and tevofioxacin in chronic respiratory tract infections
132. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease
133. Gatifloxacin treatment in patients with acute exacerbations of chronic bronchitis: Clinical trial results
134. A single-arm, noncomparative, study of oral gatifloxacin (400mg) in the treatment of patients with acute sinusitis
135. A comparison of a single oral dose of gatifloxacin versus three-day regimens of gatifloxacin or ciprofloxacin for the treatment of women with uncomplicated urinary tract infection
136. A comparison of a single dose of gatifloxacin versus three-day regimens of gatifloxacin or ciprofloxacin for the treatment of women with uncomplicated urinary tract infection
137. Single (400 mg) and multiple (200mg QD) dose oral gatifloxacin (GAT) vs multiple (100 mg BID) dose oral ciprofloxacin (CIP) in the treatment of acute uncomplicated urinary tract infection (UTI) in women
138. A multicenter comparison of gatifloxacin (GAT) 400 mg QD vs ciprofloxacin (CIP) 500 mg BID in the treatment of complicated urinary tract infection and pyelonephritis
139. Comparative study on gatifloxacin and levofloxacin in complicated urinary tract infections
140. A comparison two once-daily oral dose regimens of gatifloxacin versus twice-daily ciprofloxacin for the treatment of complicated urinary tract infection
141. A comparison two once-daily oral dose regimens of gatifloxacin versus twice-daily ciprofloxacin for the treatment of complicated urinary tract infections
142. Single-dose gatifloxacin compared with ofloxacin for the treatment of uncomplicated gonorrhea
143. Once-daily oral gatifloxacin versus oral levofloxacin in the treatment of uncomplicated skin and soft tissue infections: Double-blind multicenter, randomized study
144. Safety and tolerability of oral gatifloxacin, a new 8-methoxy fluoroquinolone: Overview of clinical data
145. A novel approach to postmarketing surveillance: The Tequin clinical experience study
146. Safety profile of the new fluoroquinolone gatifloxacin
147. Safety and tolerability of gatifloxacin, an advanced generation, 8-methoxy fluoroquinolone
148. Gatifloxacin-induced QTc prolongation and ventricular tachycardia
149. The future of the quinolones
150. Comparative tolerability of the newer fluoroquinolone antibacterials
151. Phototoxic potential of gatifloxacin, a new fluoroquinolone antimicrobial
152. Photosensitization study of gatifloxacin in guinea pigs
153. Phototoxicity studies of gatifloxacin in guinea pigs and mice
154. Phototoxicity of gatifloxacin, a new quinolone, and its related drugs in guinea pigs
155. Ecological effect of gatifloxacin on the normal human intestinal microflora
156. Effect of quinolones on intestinal ecology
157. Fluoroquinolones and respiratory tract infections: Do they work?
158. Management of adult community-acquired lower respiratory tract infections
159. Practice guidelines for the management of community-acquired pneumonia in adults
160. What is the place of fluoroquinolones in the treatment of community-acquired respiratory tract infections?
161. Gatifloxacin: A viewpoint
162. Quinolones: Which generation for which microbe?
163. Incidence of penicillin-resistant Streptococcus pneumoniae in Japan, 1993-1995
164. Efficacy of gatifloxacin in pneumococcal respiratory infection
165. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States
166. Managing antibiotic resistance
167. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenze and Moraxella catarrhalis in the United States in 1996-1997 respiratory season
168. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: Results of a 30-center national surveillance study
169. Canadian guidelines for the initial managment of community acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society
170. The clinical development of quinolone antibacterials